ADAMA Ltd. (200553.SZ) Bundle
ADAMA Ltd. (200553.SZ) sits at a crossroads: Q3 2025 sales held steady at $933 million while adjusted gross profit jumped 14% to $257 million lifting gross margin to 27.6%, yet the balance sheet still shows elevated leverage with a net debt-to-equity of 73.8% and a TTM net loss of CN¥1.49 billion (EPS -0.64); investors will want to weigh improving cash generation-operating cash flow rose to $528 million in 2024 and free cash flow turned positive at $217 million-against ongoing interest strain (EBIT interest coverage 1.2x), a modest valuation (market cap HK$13.11 billion, P/S 0.44) and upside from the three-year 'Fight Forward' plan, which targets 5-6% revenue growth in 2025 and adjusted EBITDA of $450-460 million, plus planned capex of $200-250 million and integration benefits with the Syngenta ecosystem-read on to dissect revenue trends, profitability drivers, liquidity and the key risks shaping ADAMA's investment case
ADAMA Ltd. (200553.SZ) - Revenue Analysis
ADAMA Ltd. reported mixed top-line dynamics across 2024-2025, with volume growth generally offset by price declines. Key reported figures and period-by-period drivers are summarized below.| Period | Sales (USD millions) | Volume change | Price change | Net sales change |
|---|---|---|---|---|
| Q3 2025 | 933 | +1% | -1% | Stable |
| First 9 months 2025 | 3,025 | +3% | -3% | Flat / slight mix effects |
| Q2 2025 | 1,092 | +8% | -3% | +5% |
| First half 2025 | 2,091 | +4% | -3% | Stable |
| Q4 2024 | 1,113 | +7% | -4% | -2% |
| Full year 2024 | 4,141 | 0% (stable) | -8% | -11% |
- Volume trends: consistent positive momentum in 2025 - Q2 +8%, H1 +4%, 9M +3%, Q3 +1% - indicating successful market penetration and higher unit demand.
- Price pressure: ongoing deflationary effects, notably full-year 2024 prices -8% and continuing into 2025 with -3% in H1 and -1% in Q3, limiting revenue upside despite volume gains.
- Period drivers: Q2 2025 stands out where strong volume (+8%) more than offset price declines (-3%), producing a 5% sales increase to $1,092m.
- Trailing performance: FY2024 revenue contraction (-11% to $4,141m) was primarily price-driven; volumes were stable, showing that demand did not materially fall in that year.
- Recent stability: Q3 2025 sales of $933m were effectively flat as a 1% volume gain was offset by a 1% price decline, signaling continued balance between mix and pricing.
For context on corporate direction and strategic priorities that could influence future pricing and volume dynamics, see Mission Statement, Vision, & Core Values (2026) of ADAMA Ltd.
ADAMA Ltd. (200553.SZ) - Profitability Metrics
ADAMA Ltd. shows strengthening profitability across consecutive quarters and year-to-date periods in 2024-2025, driven by lower costs and an improved product mix that lifted both adjusted gross profit and gross margins.- Q3 2025: adjusted gross profit climbed 14% to $257 million; gross margin improved to 27.6% (from 24.2% YoY).
- First nine months 2025: adjusted gross profit rose 12% to $878 million; gross margin increased to 29.0% (from 25.8% YoY).
- Q2 2025: adjusted gross profit up 18% to $318 million; gross margin improved to 29.1% (from 25.8% YoY).
- First half 2025: adjusted gross profit increased 11% to $620 million; gross margin improved to 29.7% (from 26.5% YoY).
- Q4 2024: adjusted gross profit grew 14% to $280 million; gross margin improved to 25.2% (from 21.5% YoY).
- Full year 2024: adjusted gross profit totaled $1,061 million with a gross margin of 25.6%.
| Period | Adjusted Gross Profit (USD) | Gross Margin | YoY Change in Adjusted Gross Profit |
|---|---|---|---|
| Q4 2024 | $280 million | 25.2% | +14% |
| Full Year 2024 | $1,061 million | 25.6% | - |
| Q2 2025 | $318 million | 29.1% | +18% |
| First Half 2025 | $620 million | 29.7% | +11% |
| Q3 2025 | $257 million | 27.6% | +14% |
| First Nine Months 2025 | $878 million | 29.0% | +12% |
ADAMA Ltd. (200553.SZ) - Debt vs. Equity Structure
ADAMA Ltd.'s capital structure shows elevated leverage and constrained operating coverage metrics through recent periods, with mixed signs of improvement in quarterly profitability.- Net debt to equity (Q3 2025): 73.8% - a high leverage level that implies substantial reliance on debt financing.
- Five-year trend: debt to equity rose from 62.7% to 93% at peak, reflecting increasing leverage pressures over the period.
- Operating cash flow covered 21.4% of total debt - indicating only modest capacity of cash generation to service outstanding debt principal.
- Interest coverage (EBIT / interest expense): 1.2x - limited headroom to absorb interest charges from operating profits.
- Profitability trend: Q3 2025 net loss of $48 million (improved from a $133 million loss in Q3 2024); FY 2024 net loss of $407 million (includes one-time restructuring costs) vs. $225 million loss in 2023.
| Metric | Q3 2024 | Q3 2025 | FY 2023 | FY 2024 | 5-Year Start | 5-Year Peak |
|---|---|---|---|---|---|---|
| Net Debt to Equity | - | 73.8% | - | - | 62.7% | 93.0% |
| Operating Cash Flow / Debt | - | 21.4% | - | - | - | - |
| Interest Coverage (EBIT) | - | 1.2x | - | - | - | - |
| Net Income (Loss) | ($133m) | ($48m) | ($225m) | ($407m) | - | - |
| One-time Items | - | - | - | Restructuring costs (included) | - | - |
Key balance-sheet and coverage indicators point to heightened leverage and constrained interest-service ability despite sequential improvement in quarterly net results. For context on strategic direction and how capital structure aligns with corporate priorities, see Mission Statement, Vision, & Core Values (2026) of ADAMA Ltd.
ADAMA Ltd. (200553.SZ) - Liquidity and Solvency
ADAMA Ltd.'s balance-sheet position through Q3 2025 and cash-flow performance across 2023-2024 show a mixed but improving picture: short- and long-term coverage ratios are healthy, while cash-generation improved annually despite sequential declines late in 2024.- Short-term liquidity (Q3 2025): short-term assets CN¥26.6 billion vs. short-term liabilities CN¥20.6 billion - current assets exceed current liabilities by CN¥6.0 billion.
- Long-term solvency (Q3 2025): long-term assets CN¥26.6 billion vs. long-term liabilities CN¥11.2 billion - long-term assets exceed long-term liabilities by CN¥15.4 billion.
- Operating cash flow and free cash flow trends: notable annual improvement for full year 2024, but quarter-to-quarter weakening into Q4 2024.
| Period | Short-term Assets (CN¥) | Short-term Liabilities (CN¥) | Long-term Assets (CN¥) | Long-term Liabilities (CN¥) | Operating Cash Flow (USD) | Free Cash Flow (USD) |
|---|---|---|---|---|---|---|
| Q3 2025 (balance-sheet) | 26.6 billion | 20.6 billion | 26.6 billion | 11.2 billion | - | - |
| Q4 2024 (quarter) | - | - | - | - | $126 million | $38 million |
| Q4 2023 (quarter) | - | - | - | - | $293 million | $130 million |
| Full Year 2024 | - | - | - | - | $528 million | $217 million |
| Full Year 2023 | - | - | - | - | $356 million | -$147 million |
- Quarteral cash-generation: Q4 2024 operating cash flow ($126M) was down ~57% vs. Q4 2023 ($293M); free cash flow fell ~71% from $130M to $38M.
- Annual cash-generation: FY2024 operating cash flow ($528M) improved by $172M vs. FY2023 ($356M); FY2024 free cash flow turned positive at $217M from a -$147M outflow in 2023, a swing of $364M.
- Balance-sheet cushion: with CN¥15.4 billion more long-term assets than long-term liabilities, ADAMA has headroom to support capital expenditure, debt servicing and strategic investments.
ADAMA Ltd. (200553.SZ) - Valuation Analysis
ADAMA Ltd.'s valuation profile as of December 15, 2025 presents a company trading at low sales multiples but still recovering to profitability on an earnings basis. Key headline figures frame the investment case and risk profile.| Metric | Value |
|---|---|
| Market Capitalization | HK$13.11 billion |
| TTM Revenue | CN¥29.64 billion |
| TTM Net Income | CN¥-1.49 billion (loss) |
| TTM EPS | CN¥-0.64 |
| Price-to-Sales (P/S) | 0.44 |
| Trailing P/E | Not applicable (net loss) |
| Forward P/E | 27.94 |
| 52‑Week Range | HK$1.800 - HK$3.220 |
| Beta (5y) | 0.34 |
- P/S = 0.44: implies the market values the firm's sales modestly; relative to peers in agrochemical/chemical sectors this is on the low side and can indicate undervaluation or structural margin concerns.
- Negative TTM net income and EPS (-CN¥1.49bn; -0.64 EPS): earnings weakness removes a meaningful trailing P/E signal and signals near-term profitability challenges or one‑off charges during the period.
- Forward P/E = 27.94: market-implied recovery - investors are pricing in a turnaround such that next-year earnings would justify current prices; this embeds execution and margin improvement expectations.
- Market cap HK$13.11bn vs. TTM revenue CN¥29.64bn: revenue scale is substantial versus market value, reinforcing the low P/S observation.
- 52-week range and beta 0.34: share price has shown material intra-year volatility but lower systematic risk versus the broader market, suggesting limited correlation with market swings.
ADAMA Ltd. (200553.SZ) - Risk Factors
- Highly competitive global agrochemical market: pricing pressure from overcapacity and depressed commodity prices undermines margin resilience.
- Foreign exchange exposure: Q4 2024 reported negative foreign exchange impacts that reduced sales and compressed reported top-line performance.
- Interest rate sensitivity: rising rates increase financing costs across the distribution chain, pressuring distributors and farmers and lowering demand elasticity for crop protection products.
- Leverage risk: elevated indebtedness limits financial flexibility and amplifies refinancing and covenant risks.
| Metric | Value | Notes / Period |
|---|---|---|
| Net debt to equity | 73.8% | Indicates high leverage (company-reported) |
| Operating cash flow coverage of debt | 21.4% | Ability to service debt from operating cash flow |
| Interest coverage ratio (EBIT / interest) | 1.2x | Limited capacity to cover interest from operating profits |
| FX impact (notable) | Negative in Q4 2024 | Reported reduction in sales due to currency movements |
| Market conditions | Overcapacity / low commodity prices | Ongoing pricing pressure across regions |
- Refinancing and liquidity: with an interest coverage of 1.2x and net debt-to-equity near 74%, ADAMA's ability to refinance at acceptable rates is sensitive to market tightening.
- Operational stress transmission: weaker farm economics (driven by input price volatility and higher borrowing costs) can rapidly reduce volumes and delay receivable collections, pressuring working capital.
- Currency volatility: material because ADAMA operates and sells in multiple currencies; repeated FX headwinds can erode reported revenues and margins even if underlying volumes remain stable.
- Counterparty and distributor risk: elevated interest rates can strain distributor balance sheets, increasing credit risk and potentially raising days sales outstanding.
Key financial-risk snapshot available for investor reference:
| Area | Implication for Investors |
|---|---|
| Leverage | Higher default/refinancing risk; limited balance sheet flexibility (Net debt / Equity = 73.8%). |
| Cash flow coverage | Operating cash flow covers ~21.4% of debt - moderate servicing ability; vulnerable to earnings swings. |
| Profitability vs. financing cost | Interest coverage of 1.2x signals thin buffer; rising rates could cause interest expense to outpace operating earnings. |
| FX and revenue | Negative FX in Q4 2024 demonstrates sensitivity of reported sales to currency moves. |
ADAMA Ltd. (200553.SZ) - Growth Opportunities
ADAMA Ltd. launched the 'Fight Forward' strategic transformation plan in early 2024 with explicit targets to strengthen profitability and cash generation over a three-year horizon. The plan centers on volume recovery, cost optimization through integration synergies, disciplined capital allocation, and targeted investments in growth platforms within the Syngenta Group ecosystem.- Revenue guidance: company expects 5%-6% revenue growth in 2025, driven by improving market conditions and volume growth.
- Adjusted EBITDA: projected improvement to $450M-$460M in 2025 (vs. $309M in 2023), reflecting margin recovery and cost efficiencies.
- Capex program: planned increase to $200M-$250M in 2025-2026 to support capacity, regulatory compliance and strategic projects.
- Working capital: anticipated outflow of ~ $120M in 2025, signaling inventory buildup and receivable investment to capture demand.
| Metric | 2023 (Actual) | 2025 (Guidance / Target) | Notes |
|---|---|---|---|
| Revenue growth | - (base year) | +5% to +6% | Volume-led recovery, improved market conditions |
| Adjusted EBITDA | $309 million | $450 million-$460 million | Margin recovery, synergies from Syngenta integration |
| Capex (annual) | $- (lower in recent years) | $200 million-$250 million (2025-2026) | Investment in capacity, compliance, and growth projects |
| Working capital | Neutral to modest inflow historically | ~$120 million outflow (2025) | Inventory and receivable build to support sales growth |
| Cash flow outlook | Constrained in 2023 | Improving operating cash flow; temporary headwinds from WC & capex | Focus on restoring free cash flow by late plan period |
- Primary growth catalysts: volume recovery in key geographies, cross-selling within Syngenta channels, product portfolio optimization, and targeted manufacturing investments.
- Execution risks: timing of market recovery, working-capital pressure (~$120M in 2025), and successful delivery of capex projects within $200M-$250M envelope.
- Financial impact levers: reaching the $450M-$460M adjusted EBITDA target materially improves leverage ratios and ability to fund further growth.
ADAMA Ltd. (200553.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.